Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Clinical Gastroenterology and Hepatology · 2023-04 · 21 (4) · 931-939.e5
DOI: 10.1016/j.cgh.2022.04.014 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-04. Verfasst von Cheng Han Ng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 219-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
BACKGROUND & AIMS: Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis to provide robust estimates for all-cause and liver-related mortality in biopsy-confirmed NAFLD with comparisons between fibrosis stages. METHODS: Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD. Survival estimates were pooled using reconstructed individual participant data. Conventional meta-analysis was conducted to pool adjusted hazard ratios (HRs) using DerSimonian and Laird random effects model. RESULTS: A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis. Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08-1.98), stage 3; HR, 1.96 (95% CI, 1.41-2.72), and stage 4; HR, 3.66 (95% CI, 2.65-5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44-11.5), stage 3; HR, 7.59 (95% CI, 2.80-20.5), and stage 4; HR, 15.1 (95% CI, 5.27-43.4). Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis, whereas stage 4 fibrosis had higher all-cause (HR, 2.67; 95% CI, 1.47-4.83) and liver-related mortality (HR, 2.57; 95% CI, 1.22-5.42) vs stage 3 fibrosis. CONCLUSIONS: Risk of all-cause and liver-related mortality increases substantially with fibrosis stage. These data have important implications for prognostication and trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Biostatistics & Modelling Domain, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore; National University Centre for…
- NAFLD Research Centre, University of California at San Diego, La Jolla, California; Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California. Electronic address: roloomba@…
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIAAA NIH HHS
- NHLBI NIH HHS
- Merck
- Gilead Sciences
- National Center for Advancing Translational Sciences
- Allergan
Zitieren
APA
Ng, C. H., Lim, W. H., Hui Lim, G. E., Hao Tan, D. J., Syn, N., Muthiah, M. D., Huang, D. Q., & Loomba, R. (2023). Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 21(4), 931-939.e5. https://doi.org/10.1016/j.cgh.2022.04.014
Vancouver
Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2023;21(4):931-939.e5. doi:10.1016/j.cgh.2022.04.014
BibTeX
@article{Ng2023,
author = {Ng, Cheng Han and Lim, Wen Hui and Hui Lim, Grace En and Hao Tan, Darren Jun and Syn, Nicholas and Muthiah, Mark D and Huang, Daniel Q and Loomba, Rohit},
title = {Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {4},
pages = {931--939.e5},
doi = {10.1016/j.cgh.2022.04.014}
}
EUVIMED